Intellia Therapeutics Stock Price

-4.45 (-6.23%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Intellia Therapeutics Inc NTLA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-4.45 -6.23% 66.95 19:48:50
Open Price Low Price High Price Close Price Prev Close
70.71 63.955 73.40 64.25 71.40
Bid Price Ask Price Spread News
66.55 67.85 1.30 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
26,569 1,905,929 $ 68.63 $ 130,806,497 1,936,157 9.18 - 91.9999
Last Trade Time Type Quantity Stock Price Currency
19:58:46 15 $ 66.51 USD

Intellia Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.32B 64.59M 47.84M $ 43.10M $ - -2.12 -32.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Intellia Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NTLA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week84.6185.7463.95575.861,812,930-17.66-20.87%
1 Month60.2291.999948.1671.911,941,5646.7311.18%
3 Months24.4691.999924.0156.521,606,39642.49173.71%
6 Months19.2291.999916.5442.711,195,19047.73248.34%
1 Year13.5091.99999.1831.871,033,17853.45395.93%
3 Years23.0891.99999.1825.49800,87143.87190.08%
5 Years22.0091.99999.1824.22645,41444.95204.32%

Intellia Therapeutics Description

Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.

Your Recent History
Intellia T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.